Recognized Experts in ADME / DMPK / DDI by 98% of top pharma & countless others for drug metabolism and drug-drug interaction expertise.
Learn More
May 1st Transition of XenoTech.com Products and Services to BioIVT.com
Since XenoTech joined BioIVT in Sept. 2022, we have been working to migrate all of the products and services to...
XenoTech Joins BioIVT: Expands Biospecimens Portfolio and Research Services
BioIVT, a leading provider of research models, biospecimens and research services for drug discovery and development has acquired XenoTech Along...
Webinar: New 2022 Draft ICH Drug Interaction Studies Global Guideline
Presenter: Brian Ogilvie, Ph.D, Vice President of Scientific Consulting at XenoTech Drug-drug interactions (DDI) may occur when taking two (or...
The greatest strength of XenoTech is reputation for quality. That is an easy one. Attention to detail. Quality of reports. When it comes to DMPK...
Pharma Chief Development Officer
Great reports that are ready for submission to the Agency!
Pharma Senior Vice President of R&D
Every XenoTech employee I had contact with throughout these studies have been a pleasure to work with. The entire process was seamless. I never had...
Regulatory Affairs for Small Pharma
There is a lot of quality, skilled work that has gone into this data set. Compared to organizations that have done this type of work...
ADME Consultant
Great reports that are ready for submission to the Agency!
Pharma Senior Vice President of R&D
Every XenoTech employee I had contact with throughout these studies have been a pleasure...
Regulatory Affairs for Small Pharma
There is a lot of quality, skilled work that has gone into this data...
ADME Consultant
Your drug’s journey…
Your drug’s journey…
through the body
through the pipeline
Absorption, Distribution, Metabolism, and Excretion (ADME) properties of a xenobiotic describe its disposition and inform overall fate following administration. XenoTech serves 98% of top pharma and countless others by providing high-quality contracted ADME studies and test systems to precede or support clinical trials.
Drug Metabolism & Pharmacokinetics (DMPK) is a core discipline in drug discovery and development investigating how a drug is broken down and cleared, considering both ADME and DDI characteristics to evaluate and optimize properties of a new drug compound. Our drug metabolism and pharmacokinetics testing and products allows sponsors to understand properties of their compounds and to evaluate risk early in drug development and testing.
Drug-Drug Interaction (DDI) studies allow a drug developer to investigate the potential of a xenobiotic compound to interact with drug-metabolizing enzymes and drug transporters to predict the impact on the pharmacokinetics of the compound or coadministered drugs. Drug metabolism and drug transporter studies provide critical information in evaluating potential for drug-drug interactions and associated risks in preclinical drug development.
In Silico Modeling uses mathematical models to evaluate in vitro data in a way that provides meaningful risk prediction for drug metabolism and drug interaction issues later in development or clinical trials.
In Vitro Studies & Test Systems allow drug developers to use cell-based assays to determine ADME/PK characteristics and DDI potential of their drug compound.
Our In Vivo ADME / PK Studies use radiolabeled drug compound administered to laboratory animals to investigate an investigational compound’s pharmacokinetic propertiesinclusing drug metabolism and DDI risk.
